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Abstract
Context: Osteoporosis, a disease of low bone mass, places individuals at 
enhanced risk for fracture, disability, and death. By 2025, the number of 
fractures due to osteoporosis is expected to rise to nearly three million in 
the USA alone. Pharmacological treatments for osteoporosis are aimed at 
stabilizing or increasing bone mass. However, there are significant 
drawbacks to current pharmacological options, particularly for long-term 
management of this chronic condition. Moreover, the drug development 
pipeline is relatively bereft of new strategies. Consequently, there is an 
urgent and unmet need for developing new strategies and targets for 
treating osteoporosis. 
Objective: Casual observation led us to hypothesize that much of the bone 
remodeling research literature focused on relatively few molecular 
pathways. This led us to perform bibliometric analyses to determine the 
relative popularity of bone remodeling pathways in publications and US 
National Institutes of Health funding of the last 10 years. In this review 
article, we discuss these findings and highlight several less-examined 
signaling pathways. 
Methods
• A literature search was performed in PubMed.gov using keywords
specific to bone remodeling with results from January 1, 2008 to
December 31, 2017.
• We then combined terms relating to the same signaling pathway to 
identify popular pathways in the field.
• To more narrowly examine the skeletal literature, we included the 
search term ‘osteoblast’ or ‘osteocyte’ or ‘osteoclast’.
• In order to identify lesser-studied pathways in bone remodeling, we 
excluded pathways with 50 or greater publications in the last 10 years.
• to identify particularly notable pathways for the focus of this review 
article, we generated the following inclusion criteria: (1) functional 
evidence published in a peer-reviewed journal and indexed in 
PubMed.gov, (2) fewer than ten review articles published about the 
pathway in the skeleton in the last 10 years, and (3) identifiable as a 
distinct signaling pathway.
Fig. 1 Fifty most popular
pathways in publications 
and
funded grants (indexed in
PubMed.gov and NIH 
Reporter,
respectively) from January 
1,
2008, to December 31, 
2017, as identified using 
the search terms detailed 
in Supplemental Table 2 in 
combination with the 
search Bskeleton or 
Bbone and Bsignaling or 
Bpathway and Bosteoblast
or Bosteocyte or 
Bosteoclast.
Results
Apolipoprotein D: Global ApoD KO mice exhibit low bone mass in both trabecular and cortical 
compartments of the femur that is associated with increased bone turnover rate. ApoD knockout 
mice display an increased ratio of Rankl:Opg and increased osteoclast number and decreased 
osteoblast differentiation.
Aryl Hydrocarbon receptor: When active, AhR modulates gene expression and induces
osteoclastogensis by increasing the expression of estrogen metabolizing and synthesizing 
enzymes, such as Cyp1b1 and aromatase and IL-1B, IL-6. AhR’s bone remodeling effect was
only significant when its activity was affected in osteoclast, not osteoblast.
Lysophosphatidic Acid: LPA signaling via LPA receptor 1 (LPA1) promotes 
osteoblastogenesis while LPA signaling via LPA receptor 4 (LPA4) restricts osteoblastogenesis.
Osteoclast inhibitory peptide-1: OIP-1 binds the Fc gamma receptor IIB to inhibit osteoclast 
differentiation. OIP-1 Tg mice exhibit decreased osteoclast progenitors and suppression of 
TRAF-2, c-Fos, p-c-Jun, and NFATc1 protein levels after RANKL stimulation; Spleen tyrosine 
kinase activation is also inhibited.
Oxytocin: oxytocin promotes osteoblastic differentiation of osteogenic cells in vitro. OTR is 
expressed in osteoblasts and its specific deletion in these cells leads to low bone mass.
Tas 1 Family: Consistent with a role in osteoclast function, Tas1R3 and its putative partner 
Tas1R2 are expressed in primary osteoclasts and high bone mass in Tas1R3 knockout mice is 
associated with decreased serum levels of the bone resorption marker.
NMU: global homozygous knockout of NMU leads to high trabecular bone mass in femora due 
to increased bone formation rate.
RTK: Tyro3 activation promotes osteoclast activity in vitro; global homozygous deletion of which 
leads to high bone mass in tibiae of 10-week-old mice.
ENT-1: Is involved in uptake of Adenosine; its global knockout leads to low bone mass in the 
vertebrae of 7-month-old mice and is associated with increased osteoclast number.
Fig. 2 Summary of the overall effect of the lesser 
known pathways on bone formation and resorption 
that were found in this study.
Conclusion
• our bibliometric analysis indicates a striking lack of heterogeneity within the bone remodeling 
field—with just three pathways accounting for more than 50% of publications and nearly 50% 
of funded NIH grants in this field during the last 10 years. 
• We are concerned that this current lack of diversity may restrict discovery of novel 
therapeutic.
• Here, we present brief overviews of several pathways for which functional evidence 
(genetic, pharmacological, etc.) indicates a role in the regulation of osteoblasts and/or 
osteoclasts. Additional work is required to elucidate the mechanism(s).
